pemphigus vulgaris

Argenx dealt another blow as Vyvgart Hytrulo fails again
Pharmaphorum
Wed, 12/20/23 - 09:28 am
Argenx
Vyvgart
clinical trials
Vyvgart Hytrulo
pemphigus vulgaris
Sanofi’s Principia purchase fails its first test
EP Vantage
Thu, 09/9/21 - 10:53 am
Sanofi
rilzabrutinib
Principia Biopharma
clinical trials
pemphigus vulgaris
Staying Ahead of Biosimilar Competition, Roche's Rituxan Shows Superiority in Rare Autoimmune Skin Disease
BioSpace
Mon, 10/14/19 - 11:06 am
Roche
clinical trials
Rituxan/MabThera
MMF
pemphigus vulgaris
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Endpoints
Fri, 10/11/19 - 10:40 am
AbbVie
Principia Biopharma
PRN1008
pemphigus vulgaris
Cabaletta Bio Files for $100 Million IPO
CP Wire
Wed, 10/2/19 - 10:50 am
Cabaletta Bio
IPOs
autoimmune disease
DSG3-CAART
pemphigus vulgaris
Cabaletta Bio Files for $100 Million IPO
Wed, 10/2/19 - 09:42 am
Cabaletta Bio
DSG3-CAART
pemphigus vulgaris
FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris
CP Wire
Fri, 06/8/18 - 10:07 am
Genentech
Rituxan
FDA
pemphigus vulgaris
Genentech/Roche
FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris
Fri, 06/8/18 - 10:06 am
Genentech/Roche
Rituxan
pemphigus vulgaris
Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK
Fierce Biotech
Fri, 03/11/16 - 10:36 am
Novartis
Genmab
Arzerra
GSK
pemphigus vulgaris